

Gambro introduces SelectBag® Citrate to improve quality of life for hemodialysis patients

Improving quality of life for hemodialysis patients is a primary goal of the innovative new SelectBag® Citrate concentrate from Gambro — the unique citrate-containing, acetate-free dialysis fluid for regular hemodialysis and hemodiafiltration treatment.

Citrate is a well-known antioxidant and anticoagulant and, coupled with Gambro's Individualized Quality-assured Dialysis (IQD) approach, the concentrate aims to improve treatment tolerance and dialysis efficiency.

"With our latest innovation, SelectBag® Citrate, we are offering a more physiological dialysis fluid, where citrate will add a natural metabolite that provides both energy and buffering capacity to the patient," says Juan Bosch, Senior Vice President and Chief Medical Officer at Gambro. "Patients may benefit from reduced inflammation, improved acid-base status and better tolerance to treatment. Other advantages include easier electrolyte individualization, less thrombogenic dialysis and improved overall dialysis efficiency."

SelectBag® Citrate is the latest addition to Gambro's exceptional and groundbreaking BiCart Select® system, designed to meet stringent hygiene and safety requirements. A closed flow path ensures the highest possible fluid quality, fewer technical problems, increased efficiency and individualized care for patients.

Notes to editors

[Read more about SelectBag® Citrate](#)

SelectBag® Citrate will be among products showcased at the Gambro booth at the 49th annual ERA-EDTA congress in Paris, May 2012.

[Photo of Juan Bosch, SVP Chief Medical Officer](#)

[Photo of SelectBag® Citrate](#)

Every day, Gambro's products save, sustain and improve the lives of patients worldwide through innovative products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Founded in 1964, Gambro today has 7 500 employees, production facilities in 9 countries, and sales in more than 100 countries.

www.gambro.com

For further information please contact:

Kristina Embring-Klang, Vice President Global Communications

Phone: +46734169847

Email: gambro.communications@gambro.com

References:

1. Grundstrom G, Alquist M, Holmquist M, et al., Improved acid-base status by a novel safe citrate containing acetate-free hemodialysis fluid. Abstract accepted to ERA-EDTA Congress 2012
2. Kuragano T, Kida A, Furuta M, et al., Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. *Artif Organs*. 2011 Sep 29. [Epub ahead of print]
3. Alquist M, Attman PO, Ipsen R, et al., First clinical experience with a new concentrate system for dialysis with dry sodium chloride. *ASAIO J*. 1998; 44(5):M592-5
4. Sands JJ, Kotanko P, Segal JH, et al., Effects of citrate acid concentrate on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. *Blood Purif*. 2012; 33(1-3):199-204
5. Bryland A, Wieslander A, Carlsson O, et al., Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. *Diab Vasc Dis Res*. 2012; 9(1):42-51
6. Gritters M, Grooteman MP, Schoorl M, et al., Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. *Nephrol Dial Transplant*. 2006; 21(1):153-9
7. Matsuyama K, Tomo T, Kadota J. Acetate-free blood purification can impact improved nutritional status in hemodialysis patients. *J Artif Organs*. 2011; 14(2):112-9
8. Daimon S, Dan K, Kawano M. Comparison of acetate-free citrate hemodialysis and bicarbonate hemodialysis regarding the effect of intra-dialysis hypotension and post-dialysis malaise. *Ther Apher Dial*. 2011; 15(5):460-5
9. Amore A, Cirina P, Bonaudo R, et al., Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. *J Nephrol*. 2006; 19(1):57-64
10. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. *Clin J Am Soc Nephrol*. 2009; 4(9):1459-64

Every day, Gambro's products save, sustain and improve the lives of patients worldwide through innovative products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Founded in 1964, Gambro today has 7 500 employees, production facilities in 9 countries, and sales in more than 100 countries.

www.gambro.com